COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00112021
Recruitment Status : Completed
First Posted : May 30, 2005
Last Update Posted : April 10, 2015
Information provided by (Responsible Party):

Brief Summary:
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

Condition or disease Intervention/treatment Phase
Obesity Drug: pramlintide acetate Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Study Start Date : May 2005
Actual Primary Completion Date : November 2005
Actual Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: Pramlintide Acetate Drug: pramlintide acetate
Other Name: Pramlintide acetate injection (Pramlintide (0.6 mg/mL)) is a clear, colorless, sterile solution for SC injection

Placebo Comparator: Placebo

Primary Outcome Measures :
  1. To examine the effect of pramlintide on body weight in obese subjects [ Time Frame: Approximately 16 weeks ]
  2. To examine the safety and tolerability of pramlintide in obese subjects [ Time Frame: Approximately 16 weeks ]

Secondary Outcome Measures :
  1. To investigate the effect of pramlintide in obese subjects on anthropometric and fasting/postprandial humoral metabolic parameters [ Time Frame: Approximately 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is obese with a body mass index (BMI) >=30 kg/m^2 to <=50 kg/m^2, and has been obese for at least one year before screening.
  • Usually consumes at least three major meals (morning, midday, and evening) each day.

Exclusion Criteria:

  • Is currently enrolled in a formal weight-loss program.
  • Has had liposuction within 1 year before screening or is planning to have liposuction during the study.
  • Has received any investigational drug within 3 months before screening.
  • Has previously participated in a study using pramlintide.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00112021

Layout table for location information
United States, California
Research Site
Chula Vista, California, United States
Research Site
San Diego, California, United States
Research Site
Walnut Creek, California, United States
United States, Florida
Research Site
Miami, Florida, United States
United States, Georgia
Research Site
Augusta, Georgia, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
United States, Kansas
Research Site
Overland Park, Kansas, United States
United States, Louisiana
Research Site
Baton Rouge, Louisiana, United States
United States, Michigan
Research Site
Detroit, Michigan, United States
United States, Minnesota
Research Site
Edina, Minnesota, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, Montana
Research Site
Butte, Montana, United States
United States, New York
Research Site
New York, New York, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
United States, Oregon
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Washington
Research Site
Olympia, Washington, United States
Sponsors and Collaborators
Layout table for investigator information
Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00112021    
Other Study ID Numbers: 137OB-201
First Posted: May 30, 2005    Key Record Dates
Last Update Posted: April 10, 2015
Last Verified: April 2015
Keywords provided by AstraZeneca:
weight loss
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Signs and Symptoms
Islet Amyloid Polypeptide
Hypoglycemic Agents
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Amylin Receptor Agonists
Molecular Mechanisms of Pharmacological Action